Press Releases



12/30/2020 Global Research & Discovery Group Honors the Life of Chief Strategy Advisor Lieutenant Colonel William H. ("Bill") Lyerly, Jr.


12/17/2020 GRDG Sciences Announces New Food Preservative Vanexn Successfully Inhibits Candida albicans


12/11/2020 GRDG Sciences Announces Preclinical Success of CRST-1 Medical Food as a PIM Inhibitor.


10/1/2020 Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary - Innate Immune, Inc.


9/17/2020 Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance


9/8/2020 Impact BioMedical Initiates Bioplastics Research Collaboration with One of World’s Largest Plastic Manufacturers


7/9/2020 Impact Biomedical Announces Positive Results from its In-Vitro Testing of Equivir and Linebacker, its Compounds for the Treatment of COVID-19


6/28/2020 Impact Biomedical initiates research programme to solve the patent cliff


6/24/2020 Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance


6/17/2020 Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal


6/1/2020 Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts


4/23/2020 Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts


3/19/2020 Two Promising SARS-CoV-2 Blocking Compounds Undergo Testing


7/15/2019 (Video) FOX 13 News_Laetose_Healthier Sugar


6/19/2019 Laetose(TM), Healthier Sugar Naturally Modified From Table Sugar, Unveiled at Harvard Health Summit

6/18/2019 (Video) Healthier Sugar Unveiled at Harvard Health Summit

6/12/2019 Global BioLife's new mosquito repellent formula performs well against mosquitoes in independent testing
8/30/2018  GRDG Sciences Concludes First Round of Research Achieving Objectives Resulting in a Valuation Exceeding $500 Million

2/22/2018    Odds In Their Favor: Global BioLife Makes Significant Stride In Study Of Universal Drug, Linebacker

1/10/2018    Singapore eDevelopment Limited (Stock Code: 40V)’s Biomedical Subsidiary Completes Initial Cancer Research for New Universal Therapeutic Drug Platform


1/9/2018    Global BioLife, a Biomedical Subsidiary of Singapore eDevelopment Limited, Completes Cancer Research for New Universal Therapeutic Drug Platform

1/8/2018    Singapore eDevelopment Names Former US Assistant Surgeon General, Dr Roscoe Moore, as Senior Scientific Adviser to its Biomedical Arm

11/1/2017    Singapore eDevelopment’s Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance

10/24/2017    Singapore Exchange-Listed Singapore eDevelopment’s U.S. Subsidiary Global BioLife Develops Breakthrough Modified Sugar

8/15/2017    Singapore eDevelopment Limited’s Biomedical Subsidiary forms Working Collaboration to Develop Functional Fragrances to Fight Mosquito-Borne Diseases

5/22/2017    Singapore eDevelopment Limited’s Bio-Medical Subsidiary Initiates Advanced Research of a New Universal Therapeutic Drug Platform, Led By Two-Time Nobel Prize Nominee